ArticleInfectious diseases and therapy2026
Ceftazidime-Avibactam With or Without Aztreonam Versus Other Active Antimicrobials in the Treatment of Bloodstream Infections by Carbapenem-Resistant Klebsiella pneumoniae.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCarbapenem-resistant Klebsiella pneumoniae (CRKP) bloodstream infections (BSIs) are associated with high mortality and limited treatment options. Evidence supporting ceftazidime-avibactam, with or without aztreonam, from studies exclusively with BSIs caused by CRKP remains scarce, particularly from Latin America, where there is a high burden of disease. In this study, we compared ceftazidime-avibactam-based regimens with other active antimicrobials (OAA) regimens for healthcare-associated CRKP BSIs in a Brazilian tertiary-care hospital.
methodsWe conducted a retrospective cohort study including consecutive adult patients with healthcare-associated BSIs caused by CRKP between 2014 and 2024. Patients receiving ceftazidime-avibactam with or without aztreonam were compared with those receiving OAAs. The primary outcome was 30-day all-cause mortality. Secondary outcomes included acute kidney injury (AKI), the composite of death or AKI, and post-BSI length of hospital stay. Multivariable Cox regression was performed.
resultsA total of 129 patients were included, of whom 73 received ceftazidime-avibactam-based therapy and 56 received OAAs. Carbapenemase types included class A (82.2%), class B (9.3%), and class A+B co-producing isolates (8.5%). Thirty-day mortality was significantly lower in the ceftazidime-avibactam group than in the OAA group (23.3% vs. 41.1%; P = 0.049). After adjustment, ceftazidime-avibactam-based therapy remained independently associated with lower 30-day mortality (hazard ratio, 0.51; 95% confidence interval, 0.27-0.96; P = 0.04). The composite of death or AKI was also significantly lower with ceftazidime-avibactam-based therapy (P = 0.047), whereas median post-BSI hospital stay among survivors was 8 days shorter (P = 0.06).
conclusionsIn this cohort, ceftazidime-avibactam with or without aztreonam was independently associated with lower 30-day mortality than OAAs in the treatment of CRKP BSIs. These findings extend the available evidence to BSIs caused by carbapenemase-producing isolates and support the need for broader access to ceftazidime-avibactam-based regimens in low- and middle-income countries, where therapeutic options remain limited.
Indexed as
Identifiers
42742867What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.